L
Luc Thomas
Researcher at French Institute of Health and Medical Research
Publications - 387
Citations - 25434
Luc Thomas is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Melanoma & Vemurafenib. The author has an hindex of 60, co-authored 373 publications receiving 21584 citations. Previous affiliations of Luc Thomas include Lyons & Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S. Weber,Sandra P. D'Angelo,David R. Minor,F. Stephen Hodi,Ralf Gutzmer,Bart Neyns,Christoph Hoeller,Nikhil I. Khushalani,Wilson H. Miller,Christopher D. Lao,Gerald P. Linette,Luc Thomas,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Michele Maio,Mario Sznol,Paolo A. Ascierto,Peter Mohr,Bartosz Chmielowski,Alan H. Bryce,Inge Marie Svane,Jean-Jacques Grob,Angela M. Krackhardt,Christine Horak,Alexandre Lambert,Arvin Yang,James Larkin +27 more
TL;DR: Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilicumab and a BRAF inhibitor.
Journal ArticleDOI
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin,Paolo A. Ascierto,Brigitte Dréno,Victoria Atkinson,Gabriella Liszkay,Michele Maio,Mario Mandalà,Lev V. Demidov,Daniil Stroyakovskiy,Luc Thomas,Luis de la Cruz-Merino,Caroline Dutriaux,Claus Garbe,Mika A. Sovak,Ilsung Chang,Nicholas Choong,Stephen P. Hack,Grant A. McArthur,Antoni Ribas +18 more
TL;DR: The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.
Journal ArticleDOI
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok,Bart Neyns,Gerald P. Linette,Sylvie Negrier,Jose Lutzky,Luc Thomas,William Waterfield,Dirk Schadendorf,Michael Smylie,Troy H. Guthrie,Jean-Jacques Grob,Jason Chesney,Kevin M. Chin,Kun Chen,Axel Hoos,Steven J. O'Day,Céleste Lebbé +16 more
TL;DR: Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg.
Journal ArticleDOI
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M.M. Eggermont,Vanna Chiarion-Sileni,Jean-Jacques Grob,Reinhard Dummer,Jedd D. Wolchok,Henrik Schmidt,Omid Hamid,Caroline Robert,Paolo A. Ascierto,Jon M. Richards,Céleste Lebbé,Virginia Ferraresi,Michael Smylie,Jeffrey S. Weber,Michele Maio,Lars Bastholt,Laurent Mortier,Luc Thomas,Saad Tahir,Axel Hauschild,Jessica C. Hassel,F. Stephen Hodi,Corina Taitt,Veerle de Pril,Gaetan de Schaetzen,Stefan Suciu,Alessandro Testori +26 more
TL;DR: As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.